Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials

被引:2
|
作者
Siu, Derrick H. W. [1 ,2 ]
Lin, Frank P. Y. [1 ,3 ,4 ]
Cho, Doah [1 ]
Lord, Sarah J. [1 ,5 ]
Heller, Gillian Z. [1 ,6 ]
Simes, R. John [1 ]
Lee, Chee Khoon [1 ,7 ]
机构
[1] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Camperdown, NSW, Australia
[2] Illawarra Canc Care Ctr, Dept Med Oncol, Wollongong, NSW, Australia
[3] Garvan Inst Med Res, Kinghorn Ctr Clin Genom, Darlinghurst, NSW, Australia
[4] Univ New South Wales, Sch Clin Med, Sydney, NSW, Australia
[5] Univ Notre Dame, Sch Med, Sydney, NSW, Australia
[6] Macquarie Univ, Math & Stat, Macquarie Pk, NSW, Australia
[7] St George Hosp, Canc Care Ctr, Kogarah, NSW, Australia
关键词
REAL-WORLD EVIDENCE; CAUSAL INFERENCE; CLINICAL-TRIALS; SINGLE-ARM; TASK-FORCE; CANCER; CARE; CHECKLIST; MORTALITY; SELECTION;
D O I
10.1200/PO.23.00317
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Advances in genomics have enabled anticancer therapies to be tailored to target specific genomic alterations. Single-arm trials (SATs), including those incorporated within umbrella, basket, and platform trials, are widely adopted when it is not feasible to conduct randomized controlled trials in rare biomarker-defined subpopulations. External controls (ECs), defined as control arm data derived outside the clinical trial, have gained renewed interest as a strategy to supplement evidence generated from SATs to allow comparative analysis. There are increasing examples demonstrating the application of EC in precision oncology trials. The prospective application of EC in conducting comparative studies is associated with distinct methodological challenges, the specific considerations for EC use in biomarker-defined subpopulations have not been adequately discussed, and a formal framework is yet to be established. In this review, we present a framework for conducting a prospective comparative analysis using EC. Key steps are (1) defining the purpose of using EC to address the study question, (2) determining if the external data are fit for purpose, (3) developing a transparent study protocol and a statistical analysis plan, and (iv) interpreting results and drawing conclusions on the basis of a prespecified hypothesis. We specify the considerations required for the biomarker-defined subpopulations, which include (1) specifying the comparator and biomarker status of the comparator group, (2) defining lines of treatment, (3) assessment of the biomarker testing panels used, and (4) assessment of cohort stratification in tumor-agnostic studies. We further discuss novel clinical trial designs and statistical techniques leveraging EC to propose future directions to advance evidence generation and facilitate drug development in precision oncology. External controls to evaluate outcomes in precision oncology trials: a framework and trial designs
引用
收藏
页数:12
相关论文
共 20 条
  • [1] Single-arm oncology trials and the nature of external controls arms
    Hashmi, Mustafa
    Rassen, Jeremy
    Schneeweiss, Sebastian
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (12) : 1053 - 1066
  • [2] A causal inference framework for leveraging external controls in hybrid trials
    Valancius, Michael
    Pang, Herbert
    Zhu, Jiawen
    Cole, Stephen R.
    Jonsson Funk, Michele
    Kosorok, Michael R.
    BIOMETRICS, 2024, 80 (04)
  • [3] Causal estimators for incorporating external controls in randomized trials with longitudinal outcomes
    Zhou, Xiner
    Zhu, Jiawen
    Drake, Christiana
    Pang, Herbert
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2024,
  • [4] Beyond Randomized Clinical Trials: Use of External Controls
    Schmidli, Heinz
    Haring, Dieter A.
    Thomas, Marius
    Cassidy, Adrian
    Weber, Sebastian
    Bretz, Frank
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (04) : 806 - 816
  • [5] Association between treatment toxicity and outcomes in oncology clinical trials
    Abola, M. V.
    Prasad, V.
    Jena, A. B.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2284 - 2289
  • [6] Testing for treatment effect twice using internal and external controls in clinical trials
    Yi, Yanyao
    Zhang, Ying
    Du, Yu
    Ye, Ting
    JOURNAL OF CAUSAL INFERENCE, 2023, 11 (01)
  • [7] rdborrow: an R package for causal inference incorporating external controls in randomized controlled trials with longitudinal outcomes
    Shi, Lei
    Pang, Herbert
    Chen, Chen
    Zhu, Jiawen
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2025,
  • [8] Threats to external validity in the neuroprediction of substance use treatment outcomes
    Gancz, Naomi N.
    Forster, Sarah E.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2023, 49 (01) : 5 - 20
  • [10] Visual Acuity Outcomes Among Sham vs No-Treatment Controls From Randomized Trials
    Hawkins, Barbara S.
    Bressler, Neil M.
    Reynolds, Sandra M.
    ARCHIVES OF OPHTHALMOLOGY, 2009, 127 (06) : 725 - +